Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPOCx Trial: Hypofractionated Chemoradiotherapy in Cervical Cancer
NCT07709650Phase 3Recruiting
- Sponsor
- Mahidol University
- Start
- Aug 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Cervical Cancer (CC) (2 arms), sponsored by Mahidol University. Primary endpoints: Nodal Recurrence-free Survival at 5 years and Overall Survival at 5 years. Started Aug 2026; status: recruiting.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07709650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709650.